Haemonetics (HAE)
(Delayed Data from NYSE)
$85.19 USD
-0.31 (-0.36%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $85.12 -0.07 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
HAE 85.19 -0.31(-0.36%)
Will HAE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HAE
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Medical Product Stocks to Buy From a Recovering Industry
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
Other News for HAE
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
AMD initiated, Paramount downgraded: Wall Street's top analyst calls
Haemonetics On Track for Fiscal 2026 Goals: A Buy Rating Backed by Sales Mix and Margin Optimism